Fundraising FoxSciFounders — Full Portfolio
22 tracked investments · listed companies and verified rows first
Luminate develops medical device technology to address chemotherapy side effects, particularly hair loss and peripheral neuropathy, for oncology patients and healthcare providers.
BiotechDigital HealthHealthtechMedical DevicesGalway, US
Aaron Hannon(Founder)inBarbara Oliveira(Founder)inProf. Martin O'Halloran(Co-Founder)JAMES EVERINGHAM(Executive Officer, Director)Eldad Livni(Founder)Leonid Belkind(Founder)
Co-investorsY Combinator8VCArtis VenturesAtlantic Bridge VenturesFaberGaingels+13 more
__Twitter.png)
Xterna develops xeno nucleic acid (XNA) technology to engineer cell-specific binders aimed at treating diseases currently considered untreatable.
BiotechDeep TechHealthtech
Jessica Corry(Founder)inChris Wan(Founder)in
Co-investorsReinforced VenturesBoxOne Ventures
Alga Biosciences develops feed additives that reduce methane emissions from cattle — cutting cow burps to combat climate change.
Advanced ManufacturingAgTechBiotechClimate TechSan Francisco, US
Alex Brown(Founder)inDaria Balatsky(Founder)inCaroline McKeon(Founder)inAlexander Brown(Founder)in
Co-investorsY CombinatorDay One VenturesAngel Collective Opportunity FundBBQ CapitalCollaborative FundCool Climate Collective+13 more
Coherence develops neurotechnology systems that measure and modulate brain activity to treat cancer and other neurological diseases.
AI & Machine LearningBiotechMedical DevicesSan Francisco, US
Ben Woodington(Founder)inElise Jenkins(Founder)in
Co-investorsArtesianASDF VenturesBlackbird VenturesDivergent CapitalEmpath VenturesIrregular Expressions+5 more
Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.
BiotechDeep TechHealthtechBerkeley, US
Matt Krisiloff(CEO)inBianka Seres(President)in
Co-investorsage1CompoundGaingelsHOF CapitalMaiora Rebel VenturesMetaplanet+1 more
Current Surgical develops a smart needle technology platform for surgical treatment of cancerous tumors.
Deep TechHealthtechMedical DevicesWashington, US
Al Mashal, Ph.D.(CEO / CoFounder)Chris Wagner, Ph.D.(CTO / CoFounder)
Co-investorsTrue VenturesCarbon SiliconDraper AssociatesGaingelsMBX Capital
Deliver Biosciences develops a nanoparticle-based delivery platform to genetically engineer cells inside patients (in vivo) for cell and gene therapies, using programmable targeting to transport payloads such as DNA and mRNA to specific cell types.
BiotechDeep TechHealthtech
Earth AI uses AI to locate critical mineral deposits by analyzing geological data, supporting the supply chain for hardware and emerging technologies.
Advanced ManufacturingAI & Machine LearningClimate TechDeep TechNew MaterialsSan Francisco, US
Roman Teslyuk(Founder)inRoman(Founder)
BoardIan Rountree(Director)inMikhail Taver(Director)inJamie Lee(Director)inIsabella Sykes(Director)
Co-investorsAirTree VenturesAlpaca VCBlackbird VenturesCantos VenturesCorigin VenturesDCVC (Data Collective)+26 more
EnduraTx develops small-molecule medicines that form permanent covalent bonds with disease-causing RNA to block production of proteins that cannot be drugged at the protein level, targeting conditions such as certain cancers and neurodegenerative diseases.
AI & Machine LearningBiotechDeep Tech
Co-investorsGaingelsMoxxie VenturesScribble VenturesTrue VenturesCalm Ventures
EngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
BiotechDigital HealthHealthtechSan Francisco, US
Will Olsen(Founder)inKathryn Kwant
Co-investorsCAL InnovationCalifornia Innovation FundGaingelsMetaplanetVentureSouqWorldQuant Ventures+10 more
Fletcher Bio engineers natural immune proteins using protein design to create precision immunotherapies that target and eliminate autoreactive T cells.
AI & Machine LearningBiotechDeep Tech
HarborSite develops a targeted gene insertion platform that engineers site-specific recombinase enzymes to integrate therapeutic genes into safe genomic sites.
BiotechDeep TechLongevity
Erik Aznauryan, PhD(Founder)in
Co-investorsFifty YearsSmartGateVC
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Founder)inBlake Byers(Founder)inJacob Kimmel(Founder)inMichael Polansky(Executive Officer)
BoardZavain Dar(Director)in
Co-investorsS32Valor Equity Partners8VCAbstract Venturesage1Beyond Capital+15 more
Olio Labs develops drug combination therapies using machine learning to identify treatments that target multiple interacting proteins simultaneously, with initial candidates focused on obesity treatment.
BiotechHealthtech
David Tingley(Founder)inTom Roseberry(Founder)inTim Krausz(Lead Research Engineer)
Co-investorsOverwater Ventures LlcPioneerScrum VenturesY CombinatorZAKA VC
Preventive.bio focuses on preventing disease before birth.
BiotechFemTechHealthtech
Co-investorsHOF Capital
Trace Biosciences develops technology to make nerves visible in real time during surgical procedures, enabling surgeons to better identify and preserve nerve structures.
BiotechDeep TechHealthtechMedical DevicesBeaverton, US
Connor Barth(Cofounder & CEO)inSummer Gibbs(Cofounder & CSO)Lei Wang(Cofounder & CTO)Jonathan Sorger(Director)
Co-investorsElevate Capital
Velorium develops transformational medicines by combining scientific research with patient-focused collaboration.
BiotechHealthtechMedical DevicesSan Francisco, US
Pouya Modareszadeh(CEO)inParsa Modareszadeh(COO)in
Co-investorsEight CapitalMetaplanetMyAsiaVCTranspose Platform ManagementY Combinator468 Capital+6 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Fluorescent-guided surgeryIn vivo cell editingMammoth BioSculpta
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.